Our products in combination with breast milk help to unlock the massive potential of the infant gut microbiome to build a foundation for better health.
Our Story
After years of dedicated research into the role of breast milk and its profound impact on human development, we achieved a breakthrough with B. infantis EVC001. This pioneering discovery has enabled us to develop INF108, our next-generation drug strain designed to prevent NEC in premature infants.
Our Science
There is a narrow yet optimal window of opportunity to help support gut health. Research has shown that B. infantis plays an essential role in the development of the infant microbiome.
Our B. infantis H5-positive strains demonstrate superiority in HMO utilization, achieving enhanced growth on lacto-N-tetraose and lacto-N-neotetraose, and exhibit significant fitness advantages over H5-negative strains.